These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 6207736)

  • 21. CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis.
    Koslow SH; Maas JW; Bowden CL; Davis JM; Hanin I; Javaid J
    Arch Gen Psychiatry; 1983 Sep; 40(9):999-1010. PubMed ID: 6193764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia.
    Roy A; Pickar D; Linnoila M; Doran AR; Ninan P; Paul SM
    Psychiatry Res; 1985 Aug; 15(4):281-92. PubMed ID: 2415996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The implications for antidepressant therapy of measurement of urinary MHPG.
    Moyer TP; Maruta T; Richelson E; Richardson JW
    Mayo Clin Proc; 1982 Oct; 57(10):665-7. PubMed ID: 7121073
    [No Abstract]   [Full Text] [Related]  

  • 24. Noradrenergic output and clinical response in depressed women during amitriptyline therapy.
    Corona GL; Cucchi ML; Frattini P; Santagostino G; Schinelli S; Comincioli V; Zerbi F; Fenoglio L; Savoldi F
    Pharmacopsychiatry; 1989 Jul; 22(4):144-51. PubMed ID: 2762377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical effects of antidepressant treatment--studies of monoamine metabolites in cerebrospinal fluid and platelet [3H]imipramine binding.
    Asberg M; Wägner A
    Ciba Found Symp; 1986; 123():57-83. PubMed ID: 2434288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF monoamine metabolites in mania.
    Swann AC; Secunda S; Davis JM; Robins E; Hanin I; Koslow SH; Maas JW
    Am J Psychiatry; 1983 Apr; 140(4):396-400. PubMed ID: 6188381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients.
    Lundmark J; Wålinder J; Alling C; Manniche PM; Dalgaard L
    Eur Neuropsychopharmacol; 1994 Mar; 4(1):1-6. PubMed ID: 7515737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects.
    Asberg M
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):18-26. PubMed ID: 10583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidepressant response to tricyclics and urinary MHPG in unipolar patients. Clinical response to imipramine or amitriptyline.
    Beckmann H; Goodwin FK
    Arch Gen Psychiatry; 1975 Jan; 32(1):17-21. PubMed ID: 1089399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.
    Little JT; Ketter TA; Mathé AA; Frye MA; Luckenbaugh D; Post RM
    Biol Psychiatry; 1999 Feb; 45(3):285-9. PubMed ID: 10023503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders. A replication and new findings.
    Muscettola G; Potter WZ; Pickar D; Goodwin FK
    Arch Gen Psychiatry; 1984 Apr; 41(4):337-42. PubMed ID: 6703853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders.
    Goodwin FK; Prange AJ; Post RM; Muscettola G; Lipton MA
    Am J Psychiatry; 1982 Jan; 139(1):34-8. PubMed ID: 7055275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Different urinary excretion of 3-methoxy-4-hydroxyphenyl-glycol and response to tricyclic antidepressive drugs].
    Beckmann H; Jones C; Goodwin FK
    Arzneimittelforschung; 1974 Jul; 24(7):1010-2. PubMed ID: 4408047
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacotherapy of depression--a critical review.
    Ban TA
    Psychosomatics; 1975; 16(1):17-20. PubMed ID: 1101282
    [No Abstract]   [Full Text] [Related]  

  • 35. Urinary MHPG levels and tricyclic antidepressant drug selection. A preliminary communication on improved drug selection in clinical practice.
    Cobbin DM; Requin-Blow B; Williams LR; Williams WO
    Arch Gen Psychiatry; 1979 Sep; 36(10):1111-5. PubMed ID: 475544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemistry and treatment strategies for depression.
    Garvey MJ
    J Fam Pract; 1980 Aug; 11(2):215-9. PubMed ID: 6106040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toward a biochemical classification of depressive disorders IV: Pretreatment urinary MHPG levels as predictors of antidepressant response to imipramine.
    Schatzberg AF; Orsulak PJ; Rosenbaum AH; Maruta T; Kruger ER; Cole JO; Schildkraut JJ
    Commun Psychopharmacol; 1980; 4(5):441-5. PubMed ID: 7333096
    [No Abstract]   [Full Text] [Related]  

  • 38. MHPG as a predictor of antidepressant response to imipramine and maprotiline.
    Rosenbaum AH; Schatzberg AF; Maruta T; Orsulak PJ; Cole JO; Grab EL; Schildkraut JJ
    Am J Psychiatry; 1980 Sep; 137(9):1090-2. PubMed ID: 7425162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-Hydroxytryptophan-induced cortisol response and CSF 5-HIAA in depressed patients.
    Koyama T; Lowy MT; Meltzer HY
    Am J Psychiatry; 1987 Mar; 144(3):334-7. PubMed ID: 2435178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current biochemical hypotheses of endogenous depression].
    Riederer P; Beckmann H; Brücke T
    Wien Klin Wochenschr; 1985 Feb; 97(4):190-6. PubMed ID: 2580396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.